Pages that link to "Q36646353"

The following pages link to Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function (Q36646353):

Displaying 42 items.

• Smad7 is required for the development and function of the heart (Q24309082) (← links)
• New Molecular Insights of Insulin in Diabetic Cardiomyopathy (Q26752678) (← links)
• Molecular basis of physiological heart growth: fundamental concepts and new players (Q27006868) (← links)
• Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth (Q27320013) (← links)
• Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway (Q29568312) (← links)
• Insulin Signaling and Heart Failure. (Q30377910) (← links)
• A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice (Q33449060) (← links)
• MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice (Q34028756) (← links)
• P53 inhibition exacerbates late-stage anthracycline cardiotoxicity (Q34048273) (← links)
• Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation (Q34307302) (← links)
• mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy (Q34426387) (← links)
• Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin (Q34627013) (← links)
• Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. (Q34627120) (← links)
• Cardiac Insulin Resistance and MicroRNA Modulators (Q35251097) (← links)
• Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities (Q35789287) (← links)
• PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? (Q36025665) (← links)
• Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart (Q36061754) (← links)
• Loss of long-chain acyl-CoA synthetase isoform 1 impairs cardiac autophagy and mitochondrial structure through mechanistic target of rapamycin complex 1 activation. (Q36171264) (← links)
• Polymerase delta-interacting protein 2 regulates collagen accumulation via activation of the Akt/mTOR pathway in vascular smooth muscle cells (Q36779215) (← links)
• Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy. (Q37510124) (← links)
• Mammalian target of rapamycin signaling in cardiac physiology and disease. (Q37715817) (← links)
• Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure (Q37883418) (← links)
• The functions of mTOR in ischemic diseases (Q37922815) (← links)
• Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies (Q38030250) (← links)
• The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway (Q38243667) (← links)
• Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish (Q38294246) (← links)
• Fuel availability and fate in cardiac metabolism: A tale of two substrates (Q38781072) (← links)
• Loss of Hand2 in a population of Periostin lineage cells results in pronounced bradycardia and neonatal death (Q38809995) (← links)
• The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure. (Q38941373) (← links)
• Impact of caloric restriction on myocardial ischaemia/reperfusion injury and new therapeutic options to mimic its effects (Q40630534) (← links)
• Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway (Q41884318) (← links)
• Blockade of the acute activation of mTOR complex 1 decreases hypertrophy development in rats with severe aortic valve regurgitation (Q42042549) (← links)
• Target of rapamcyin (TOR)-based therapeutics for cardiomyopathy: insights from zebrafish genetics (Q42562973) (← links)
• Roles and controls of mTOR in the heart. Focus on "mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy". (Q42868139) (← links)
• Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines (Q47800119) (← links)
• New Insights Into the Role of mTOR Signaling in the Cardiovascular System. (Q48506350) (← links)
• Exercise training reduces insulin resistance and upregulates the mTOR/p70S6k pathway in cardiac muscle of diet-induced obesity rats (Q51393004) (← links)
• GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways (Q51891379) (← links)
• Links between mTOR and the immunoproteasome: Therapeutic targets for cardiac hypertrophy? (Q53516074) (← links)
• Mechanical Regulation of Protein Translation in the Cardiovascular System (Q89823740) (← links)
• Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity (Q93035180) (← links)
• Lack of muscle mTOR kinase activity causes early onset myopathy and compromises whole-body homeostasis (Q93264363) (← links)